Blockchain Registration Transaction Record

Vycor Medical Q1 2026: Revenue Up 5%, Turns Operating Profit

Vycor Medical Q1 2026 results show 5% revenue growth, operating profit of $45,808, and new clinical studies validating ViewSite Brain Access System for safer neurosurgery.

This news matters because Vycor Medical's financial turnaround and the positive clinical data on its ViewSite Brain Access System (VBAS) signal a growing acceptance of minimally invasive neurosurgery, which can lead to better patient outcomes with fewer complications. For investors, the company's path to profitability and international expansion suggest a strengthening business model. For patients and healthcare providers, the evidence from new studies reinforces VBAS as a safer alternative to traditional retractors, potentially reducing neurological deficits after brain surgery. Additionally, NovaVision's therapies address a critical unmet need for vision recovery after stroke, impacting millions of patients worldwide.